UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
12 mars 2024 14h06 HE
|
Fractyl Health, Inc.
Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
12 mars 2024 08h38 HE
|
Fractyl Health, Inc.
Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
06 mars 2024 23h58 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing...
Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements
06 mars 2024 06h55 HE
|
ANTION BIOSCIENCES SA
Antion Biosciences release in vivo proof-of-concept data for miCAR7 and milestone achievement for Allogene Therapeutics
Asia-Pacific Gene Editing Technology Research Report 2024
29 févr. 2024 10h03 HE
|
Research and Markets
Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Gene Editing Technologies Market: Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering.The...
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
28 févr. 2024 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly...
Europe Cell and Gene Therapy Manufacturing QC Market Research Report 2024
28 févr. 2024 09h29 HE
|
Research and Markets
Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "Europe Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.The...
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
28 févr. 2024 07h05 HE
|
uniQure Inc.
~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory...
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
27 févr. 2024 16h30 HE
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, 2023-2033: Rising Number of Approved Therapies and Increasing Need for Expanded Infrastructure
27 févr. 2024 06h46 HE
|
Research and Markets
Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's...